Consensus AB Science

Equities

AB

FR0010557264

Market Closed - Euronext Paris Other stock markets 11:35:15 2024-04-26 am EDT			5-day change	1st Jan Change
1.936 ^EUR	+2.76%		-1.63%	-45.54%

Apr. 04	AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	MT
Apr. 03	AB Science: reconsideration possible for masitinib in ALS	CF

Evolution of the average Target Price on AB Science

Price target over the last 5 years

History of analyst recommendation changes

1dfb33a201b847aa756.EoOoyPXMkM_wBHWcaga0imWwOEyRika4K9h0E40Kk8o.RtOdho-Z0b3ETAKsP2z58gzWUSil_GvQTbZZeudd9Zxb6-Dlm_vTrLVHHg~c14f4da128cb26f57f94ab4d27131e72

Analyst Recommendations on AB Science

AB Science : Masitinib Treatment Against Pancreatic Cancer Boosts Survival Rates	20-12-04	MT
SCIENCE : AB Science: Chardan Capital Markets initiates coverage with a BUY recommendation on AB Science and a target price of €30	15-05-05	GL

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.936 EUR

Average target price

6.895 EUR

Spread / Average Target

+256.15%

High Price Target

10 EUR

Spread / Highest target

+416.53%

Low Price Target

3.79 EUR

Spread / Lowest Target

+95.76%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar